Table 1.

Patient baseline demographics and disease characteristics

Characteristicsn (%) or median (range)
(N = 43)
Hepatocellular carcinoma, n (%)18 (41.9%)
Age, years, median (range)49 (29–64)
Gender, n (%)
 Male17 (94.4%)
 Female1 (5.6%)
ECOG, n (%)
 010 (55.6%)
 18 (44.4%)
Liver cirrhosis, n (%)
 Yes13 (72.2%)
 No5 (27.8%)
Etiology of HCC, n (%)
 Hepatitis B18 (100.0%)
 Hepatitis C0
Macrovascular invasion, n (%)
 Yes6 (33.3%)
 No12 (66.7%)
Extrahepatic disease, n (%)
 Yes16 (88.9%)
 No2 (11.1%)
Macrovascular invasion and/or extrahepatic disease, n (%)
 Yes17 (94.4%)
 No1 (5.6%)
Baseline Child-Pugh score, n (%)
 58 (44.4%)
 65 (27.8%)
 75 (27.8%)
BCLC stage, n (%)
 A0
 B1 (5.6%)
 C17 (94.4%)
Prior therapies (HCC), n (%)
 ≥2 Locoregional proceduresa12 (66.7%)
 Surgery12 (66.7%)
 Ablation9 (50.0%)
 TACE/TAE15 (83.3%)
 Sorafenibb15 (83.3%)
GC and EGJC, n (%)25 (58.1%)
Age, years, median (range)54 (34–68)
Gender, n (%)
 Male15 (60.0%)
 Female10 (40.0%)
ECOG, n (%)
 06 (24.0%)
 119 (76.0%)
Histology subtype (Lauren classification), n (%)
 Intestinal4 (16.0%)
 Diffuse6 (24.0%)
 Mixed4 (16.0%)
 Unknown11 (44.0%)
Extent of disease, n (%)
 Metastatic24 (96.0%)
 Locally advanced1 (4.0%)
Number of metastatic sites, n (%)
 1–214 (56.0%)
 ≥311 (44.0%)
Prior therapies (GC/EGJC), n (%)
 Surgery16 (64.0%)
 First-line therapyc9 (36.0%)
 >First-line therapyd16 (64.0%)
  • Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; TACE, transcatheter arterial chemoembolization; TAE, transcatheter embolization.

  • aIncludes ablation, transcatheter arterial chemoembolization, and transcatheter embolization.

  • bReasons for previous treatment failure with sorafenib therapy included disease progression [14 (93.3%)] and sorafenib intolerance [1 (6.7%)].

  • cFirst-line therapy included taxane and fluoropyrimidine [4 (44.4%)], platinum and fluoropyrimidine [3 (33.3%)], platinum and irinotecan [1 (11.1%)], fluoropyrimidine [1 (11.1%)].

  • dIn patients who had received more than one line of therapy, first-line therapy included platinum and fluoropyrimidine [11 (68.8%)], taxane and fluoropyrimidine [2 (12.5%)], platinum and irinotecan [2 (12.5%)], fluoropyrimidine and adriamycin [1 (6.3%)]; second-line therapy included taxane and fluoropyrimidine [7 (43.8%)], taxane and platinum [2 (12.5%)], taxane and irinotecan [2 (12.5%)], platinum and fluoropyrimidine [1 (6.3%)], raltitrexed and irinotecan [1 (6.3%)], taxane [1 (6.3%)], fluoropyrimidine [1 (6.3%)], apatinib [1 (6.3%)].